DOCSLIB.ORG

Chemical Compatibility Chart for Plazit-Polygal PLAZGAL SAN Sheets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Chemical Compatibility Chart for Plazit-Polygal PLAZGAL SAN Sheets This table gives an indication of the chemical resistance of PLAZGAL SAN sheets to a range of common chemicals at 20ºC. PLAZGAL SAN sheets can be safely used with most chemicals and components such as alkalis and diluted acids, as well as with aqueous salt solutions. However, SAN has limited resistance to alcohols, aliphatic hydrocarbons, oils and fats, and is not resistant to concentrated mineral acids, aromatic and/ or halogenated hydrocarbons, esters, ethers, ketones. Important note: the chemical stability of PLAZGAL SAN sheets depends on many factors such as the concentration of the chemical agent, internal stresses in the sheets and exposure temperature, in certain situations the sheets can develop stress cracks when even when exposed to chemicals to which SAN is usually resistant. The resistance of PLAZGAL SAN sheets is indicated in the table below. Chemical Concentration Compliance Chemical Concentration Compliance Aqua Regia Dissolved Brake fluids (ATE) Affected Acetic acid To 50% Not affected Butter Not affected Acetic acid 100% Affected Butyl acetate Affected Acetone Affected Butyric acid Affected Acetylsalicylic (soln.) Not affected Cadmium (soln.) Not affected acid bromide Allyl alcohol Affected Caffeine (soln.) Not affected Almond, bitter, Not affected Calcium bromide (soln.) Not affected oil of Calcium chloride (soln.) Not affected Aluminium (soln.) Not affected Calcium (solid) Not affected chloride hypochlorite Aluminium (soln.) Not affected Calcium (soln.) Not affected sulfate hypochlorite Ammonia, 25% Not affected Calcium oxide Not affected aqueous Camphor Not affected Ammonium car- (soln.) Carbon dioxide Not affected bonate Carbon sulfide Affected Not affected Carnauba wax Not affected Amyl acetate Affected Castor oil Not affected Barium chloride (soln.) Not affected Cetyl alcohol Not affected Barium bromide (soln.) Not affected Chlorinated lime Not affected Barium (soln.) Not affected Chloroform Affected carbonate Chlorine (liquid or gase- Affected Benzaldehyde Affected ous) Benzene Affected Chlorine water Dissolved Benzole acid Not affected Chloroacetic acid Dissolved Benzyl acetate Affected Chlorobenzene Affected Benzyl alcohol Affected Citronella, oil of Affected Bismuth chloride (soln.) Not affected Chromosulfuric Affected Bismuth (soln.) Not affected acid subnitrate Chlorosulfonic Affected Borax (soln.) Not affected acid Boric acid (soln.) Not affected Cider (apple) Not affected Butane Not affected Cinnamic Affected Bromine liquid Affected aldehyde 1 Chemical Concentration Compliance Chemical Concentration Compliance Citric acid (soln.) Not affected Gallic acid Not affected Coconut oil Not affected Gasoline Dissolved Copper Sulfate (soln.) Not affected Glucose (30 %) Not affected Chromic acid (soln.) Affected Glycerin Not affected Cod-liver oil Not affected Grapefruit juice Not affected Cloves, oil of Not affected Gravy Not affected Coffee extract Not affected Heptane Dissolved Cottonseed oil Not affected Heptyl alcohol Not affected Cresol (para) Dissolved Hexachlorobenzene Not affected Cyclohexane Not affected Hexane Dissolved Cyclohexanol Not affected Hexanetriol Not affected Cyclohexanone Dissolved Hexanol Not affected Dairy products Not affected Honey Not affected Dehydroacetic Household (soln.) Not affected acid deter-gent Not affected Hydrochloric acid Not affected Diacetone Affected Hydrofluoric acid To 40% Not affected alcohol Hydrogen 30% Not affected Dibutyl phthalate Affected Dioxide Dichlorobenzene Affected (peroxide) Diesel fuel Not affected Hydrogen sulfide Not affected Diethanolamine Not affected Hydroquinone (soln.) Not affected Diethyl ether Affected Hydroxyacetone Dissolved Diethyl hexyl Not affected Ink, writing Not affected phthalate Iodine, tincture Dissolved Diethyl ketone Not affected of Diethyl phthalate Affected Iron (II) chloride (solid) Not affected Diethylene glycol Not affected Iron (II) sulfate (solid) Not affected Disodecyl Affected Iron ammonium Not affected phthalate sulfate Dimethyl Affected Iron nitrate Not affected phthalate (soln.) Dimethylformamide Affected Isoamyl alcohol Not affected Dinonyl Dissolved Isobutanol Dissolved phthalate Isooctane Not affected Dioxane (1,4 dioxane) Affected Isopropanol Dissolved Diphenyl ether Affected Isopropyl acetate Affected Diphenylamine Lactic acid To 80 % Not affected Affected Lactose (soln.) Not affected Ethanol To 95% Not affected Lanolin Not affected Ether (Diethyl Affected Lauryl alcohol Not affected ether) Lead sulfate (soln.) Not affected Ethyl Acetate Affected Magnesium Not affected Ethyl chloride Affected bromide Ethylbenzol Affected Magnesium car- Not affected Ethylene chloride Affected bonate Ethylene glycol Not affected Magnesium (soln.) Not affected Eucalyptus, oil of Not affected chloride Fertilizer salts Not affected Magnesium (soln.) Not affected Formaldehyde 30% Not affected sulfate Formic acid To 40% Not affected Maize oil Not affected Formic acid To 85% Dissolved Malic acid (10%) Not affected Freon 11 Dissolved Mercury chloride (soln.) Not affected Freon 22 Dissolved Methanol Dissolved Furfural Affected Methyl acetate Affected Furfuryl alcohol Dissolved Methyl butanol Not affected 2 Chemical Concentration Compliance Chemical Concentration Compliance Methyl chloride Affected Potassium Not affected Methyl Not affected chloride (soln.) cyclohexane Potassium Not affected Methyl ethyl Affected chromate (soln.) ketone Potassium Not affected Methyl isobutyl Affected dichro- ke-tone mate(soln.) Methyl isopropyl Affected Potassium Not affected ketone ferricya-nide Methyl propyl Affected Potassium (soln.) Not affected ke-tone fluoride Methyl salicylate Affected Potassium Not affected Methylene Affected hydroxide chloride Potassium (soln.) Not affected Methylene Affected iodate chloro-bromide Potassium iodide (soln.) Not affected Milk Not affected Potassium (soln.) Not affected Motor oil Not affected nitrate (automo-tive) Potassium (soln.) Not affected n-Butanol Not affected perman-ganate n-Nonanol Not affected Potassium (soln.) Not affected n-Octanol Not affected persul-fate n-Propanol Not affected Potassium (soln.) Not affected sulfate Naphthalene (solid) Not affected Potassium (soln.) Not affected Naphthalene (soln. in ethanol) Dissolved sulfide Nickel sulfate (soln.) Not affected Propane (liquid) Not affected Nitric acid (30 %) Not affected Propylene Affected Nitric acid (conc.) Affected chloride Nitrobenzene Affected Propylene glycol Not affected Oleic acid Not affected Salicylic acid (soln.) Not affected Olive oil Not affected Sea water Not affected Orange, oil of Not affected Sebacic acid Affected Oxalic acid (soln.) Not affected dibutyl ester Ozone (<0,5 ppm) Not affected Silicone fluid Not affected Palm oil Not affected Silver nitrate (soln.) Not affected Palmitic acid Not affected Sodium acetate (soln.) Not affected Paraffin oil Not affected Sodium (soln.) Not affected Peanut oil Not affected benzoate Pectin (soln.) Not affected Sodium (soln.) Not affected Pentane Dissolved bicarbonate Peppermint,oil of Affected Sodium bisulfite (soln.) Not affected Perchloroethylene Affected Sodium borate (soln.) Not affected Petroleum ether Dissolved Sodium bromate (soln.) Not affected Petroleum jelly Dissolved Sodium bromide (soln.) Not affected Phenacetin Not affected Sodium (soln.) Not affected Phenol Affected carbonate Phenylethanol Affected Sodium chloride (soln.) Not affected Phosphoric acid (to 85 %) Not affected Sodium chloride (dry, soln.) Not affected Phthalic acid (soln.) Not affected Sodium (soln.) Not affected Potassium Not affected chromate alumini-um Sodium Not affected Potassium Not affected hydrogen sulfite bisulfate Sodium To 50% Not affected Potassium Not affected hydroxide bromate (soln.) Sodium (soln., 12 % Not affected Potassium Not affected hypochlorite chlorine) bromide (soln.) Sodium nitrate Not affected 3 Chemical Concentration Compliance Chemical Concentration Compliance Sodium nitrite Not affected Transformer oil Not affected Sodium (soln.) Not affected Trichlorobenzene Affected perborate Trichloroethane Affected Sodium (sec., soln., tert.) Not affected Trichloroethylene Affected phosphate Trichlorophenol Affected Sodium sulfate (soln.) Not affected Tricresyl Affected Sodium sulfide (soln.) Not affected phosphate Sodium sulfite (soln.) Not affected Triethanolamine Not affected Sodium (soln.) Not affected Triethylene glycol Not affected thiosulfate Triglycol acetate Affected Soy oil Not affected Trypaflavin (R) Not affected Stearic acid Not affected Tryptophane (d Not affected Strontium Not affected or I) bromide Turpentine Dissolved Strychnine Not affected Tung Oil pure Not affected Sugar (soln., 30 %) Not affected Urea (soln.) Not affected Sulfur Not affected Urotropin (soln.) Not affected Sulfur Not affected Undecyl Alcohol pure Not affected hexafluoride Valerian drop Not affected Sulfiric acid To 50% Not affected Verbena oil Dissolved Sulfiric acid Conc. Affected Vinegar Not affected Trichloroethane Affected Water Not affected Tetrachlorom Affected Wax (bleached) Not affected ethane White oil Not affected Tetrahydrofuran Affected Xylene Affected Tetrahydrofurfurol Affected Zinc bromide Not affected Tetralin (R) Affected Zinc carbonate Not affected Thionyl chloride Affected Zinc chloride (soln.) Not affected Thiophene Affected Zinc nitrate Not affected Thymol Affected Zinc oxide Not affected Toluene Affected Zinc stearate Not affected Tomato juice Not affected Zinc sulfate (soln.) Not affected 4 DISCLAIMER: The data in this advertisement are provided in good faith and constitute general information without commitment and no warranty is given or implied. Our plastics products are a combustible thermoplastic that complies with various international standards, as customary in each country. Avoid exposure to excessive heat or aromatic cleaning solvent. Normal fire precautions should be taken to protect against combustion. Plazit Polygal Group YOUR LOCAL [email protected] | Tel: +972.4.662.8888 | www.plazit-polygal.com STRATEGIC PARTNER REV 01 06/2020 EE.
Recommended publications
  • Vademecum Agrovet Market Animal Health

    Vademecum Agrovet Market Animal Health

    Vademecum Agrovet Market Animal Health We are a Peruvian company focused on the development, production and commercialization of veterinary products, driving its technical and creative development to meet the needs of veterinarians and stock farmers with unique products of high quality. www.agrovetmarket.com Mission l Products of Unique Class Provide veterinary, nutritional and farmaceutical products of unique class; developed in a creative and innovative way, under high standards of quality that allow us to reach international markets and consolidate locally through the formal stablishment of strategical alliances. Antibiotics Line of large animals am Line of companion animals ac Line of poultry and swine av www.agrovetmarket.com Antibiotics ® Agrogenta 11 | Vetigen 11 Injectable Solution Broad-spectrum aminoglycoside Composition: Gentamicin (as sulphate) 110 mg, excipients q.s. ad 1 mL. Indications: Treatment and prevention of infections caused by microorganisms sensitive to gentamicin (of the urogenital, respiratory and gastrointestinal systems). Also useful in cases of mastitis, metritis, post-operatory and cutaneous infections, septicemias, among others.. Dosage and Administration: Cattle, horse, sheep, goat, swine, camelid: 1 mL/27.5 kg of b.w.; young animals, dogs and cats: 1 mL/14 kg; poultry: 0.1 mL/1.4 kg; every 24 hours for 3 to 5 consecutive days by subcutaneous or intramuscular route. Intrauterine or intra-mammary route: Cows: 2 mL diluted in 20 mL of physiological saline solution for 3 to 5 days. Mares: 20 mL diluted in 200 - 500 mL of physiological saline solution for 3 to 5 days (only intrauterine route). Commercial Presentation: Bottle x 100 mL and 250 mL.
  • Sodium Bromate

    Sodium Bromate

    Sodium bromate sc-251012 Material Safety Data Sheet Hazard Alert Code EXTREME HIGH MODERATE LOW Key: Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Sodium bromate STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY0 HEALTH2 HAZARD INSTABILITY2 OX SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS NaBrO3, "bromic acid, sodium salt" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability 0 Toxicity 2 Body Contact 2 Min/Nil=0 Low=1 Reactivity 2 Moderate=2 High=3 Chronic 3 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 10 CANADIAN WHMIS CLASSIFICATION CAS 7789-38-0Sodium bromate C-Oxidizing Material 1 EMERGENCY OVERVIEW RISK Contact with combustible material may cause fire. Harmful if swallowed. May cause CANCER. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ■ Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ■ Bromide poisoning causes intense vomiting so the dose is often removed. Effects include drowsiness, irritability, inco-ordination, vertigo, confusion, mania, hallucinations and coma. ■ Bromate poisoning almost always causes nausea and vomiting, usually with pain of the upper abdomen. Loss of hearing can occur, and bromates damage the kidneys. EYE ■ This material can cause eye irritation and damage in some persons.
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al

    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
  • Safety Data Sheet Breaker J481

    Safety Data Sheet Breaker J481

    SDS no. J481 Version 2 Revision date 10-Aug-2017 Supersedes date 11-Sep-2015 Safety Data Sheet Breaker J481 1. Identification of the substance/preparation and of the Company/undertaking 1.1 Product identifier Product name Breaker J481 Product code J481 1.2 Relevant identified uses of the substance or mixture and uses advised against Recommended Use Used as a fracturing additive in oilfield applications Uses advised against Consumer use 1.3 Details of the supplier of the safety data sheet Supplier Schlumberger Oilfield Australia Pty Ltd ABN: 74 002 459 225 ACN: 002 459 225 256 St. Georges Terrace, Perth WA 6000 +47 5157 7424 [email protected] 1.4 Emergency Telephone Number Emergency telephone - (24 Hour) Australia +61 2801 44558, Asia Pacific +65 3158 1074, China +86 10 5100 3039, Europe +44 (0) 1235 239 670, Middle East and Africa +44 (0) 1235 239 671, New Zealand +64 9929 1483, USA 001 281 595 3518 Denmark Poison Control Hotline (DK): +45 82 12 12 12 Germany +49 69 222 25285 Netherlands National Poisons Information Center (NL): +31 30 274 88 88 (NB: this service is only available to health professionals) 2. Hazards Identification 2.1 Classification of the substance or mixture Classification according to Regulation (EC) No. 1272/2008 [CLP] Health hazards Acute toxicity - Oral Category 4 Skin corrosion/irritation Category 2 Serious eye damage/eye irritation Category 2 Germ cell mutagenicity Category 2 Carcinogenicity Category 1B Specific target organ toxicity - Single exposure Category 3 Environmental hazards Not classified _____________________________________________________________________________________________ Page 1 / 12 Breaker J481 SDS no.
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
  • Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey

    Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey

    Public Use Data Ta~e Documentation 1992 National Ambulatory Medical Care Survey From the CENTERS FOR DISEASE CONTROL AND PREVENTION/Nutional Center for Health Stdklics -—..—=-.=-=.-.‘,.- . ----. - . .- -,-- -.-- .--.,. -’ ‘ --- - –.--.------ ,-:-.-,J ----- ---------- ---P ------.-->- — .. ..- --. : _ U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Publlc Health Service Centers for Disease Control and Prevention National Center for Health Statistics CDCcE141EmFonmEUEcoumoL WMEmmm Public Use Data Tape Documentation 1992 National Ambulatory Medical Care Survey U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention National Center for Health .SJatistics Hyattsville, Maryland November 1994 299 2 NAMcs MICRO-DATA TAPE Docum NTATION PAGE 1 ABSTRACT This material provides documentation for users of the Micro-Data tapes of the National Ambulatory Medical Care Suney (NAMCS) conducted by the National Center for Health Statistics. Section I, “Description of the National Ambulatory Medical Care Sumey,” includes information on the scope of the amm.rey,the sample, field activities, data collection procedures, medical coding procedures, population estimates, and sampling errors. Section II provides technical detaile of the tape (number of tracks, record length, etc.), and a detailed description of the contents of each data record by location. Section III contains marginal data or estimates for each item on the data record in Section II. The appendixes contain santplingerrors, instructions and definitions for completing the Patient Record Form, and list~ of codes used in the survey. TABLE OF CONTENTS PAGE I. Description of the National Ambulatory Medical Care SuNey 2-14 Distribution of physicians (Table I) 4 Population Figures (Table II) 6 Patient Log and Patient Record Form (Figure 1) 8 References 14 II.
  • Valerian Root Valeriana Officinalis L., Radix

    Valerian Root Valeriana Officinalis L., Radix

    5 April 2016 EMA/152385/2016 Herbal medicine: summary for the public Valerian root Valeriana officinalis L., radix This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of valerian root. The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing valerian root. This summary is not intended to provide practical advice on how to use medicines containing valerian root. For practical information about using valerian root medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. What is valerian root? Valerian root is the common name for the underground parts of the plant Valeriana officinalis L. The HMPC conclusions only cover valerian root preparations which are obtained by drying and comminuting (reducing into tiny pieces) or powdering the underground parts of the plant, by expressing the juice of the fresh root, and as dry or liquid extracts. Extracts are prepared using a technique to extract compounds by putting the plant material in a solvent (such as ethanol, methanol or water) to dissolve compounds and form a liquid extract. For dry extracts, the solvent is then evaporated off. Herbal medicines containing comminuted valerian root are usually available as herbal tea to be drunk or as bath additives. The other herbal preparations of valerian root are available in solid or liquid form to be taken by mouth. Valerian root preparations may also be found in combination with other herbal substances in some herbal medicines.
  • Interactions with Protease Inhibitors Charts Revised February 2018

    Interactions with Protease Inhibitors Charts Revised February 2018

    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
  • Updating the Biological Interest of Valeriana Officinalis

    Updating the Biological Interest of Valeriana Officinalis

    ARTICLES Mediterranean Botany ISSNe 2603-9109 https://dx.doi.org/10.5209/mbot.70280 Updating the biological interest of Valeriana officinalis Marta Sánchez1 , Elena González Burgos1 , Irene Iglesias1 & M. Pilar Gómez-Serranillos1 Received: 23 June 2020 / Accepted: 5 August 2020 / Published online: 11 January 2021 Abstract. Valeriana officinalis L. (Caprifoliaceae) has been traditionally used to treat mild nervous tension and sleep problems. The basis of these activities are mainly attributed to valerenic acid through the modulation of the GABA receptor. Moreover, V. officinalis is claimed to have other biological activities such as cardiovascular benefits, anticancer, antimicrobial, and spasmolytic. The current review aims to update the biological and pharmacological studies (in vitro, in vivo, and clinical trials) of V. officinalis and its major secondary metabolites to guide future research. Databases PubMed, Science Direct, and Scopus were used for literature search, including original papers written in English and published between 2014 and 2020. There have been identified 33 articles that met the inclusion criteria. Most of these works were performed withV. officinalis extracts, and only a few papers (in vitro and in vivo studies) evaluated the activity of isolated compounds (valerenic acid and volvalerenal acid K). In vitro studies focused on studying antioxidant and neuroprotective activity. In vivo studies and clinical trials mainly investigated the nervous system activity (anticonvulsant activity, antidepressant, cognitive problems, anxiety, and sleep disorders). Just a few studies were focused on other different activities, highlight effects on symptoms of premenstrual and postmenopausal syndromes. Valeriana officinaliscontinues to be one of the medicinal plants most used by today’s society for its therapeutic properties and whose biological and pharmacological activities continue to arouse great scientific interest, as evidenced in recent publications.
  • Chemical Waves

    Chemical Waves

    Chemical Waves Equipment: two beakers (50 mL) two beakers (100 mL) graduated cylinder (100 mL) volumetric pipet (2 mL) two volumetric pipets (10 mL) magnetic stirrer with stir bar spatula Petri dish (diameter: 10 cm) overhead projector and black cardboard Chemicals: sodium bromate concentrated sulfuric acid malonic acid sodium bromide ferroin indicator solution (0.1 wt.%) deionized water Safety: sodium bromate (NaBrO3): H272, H302, H315, H319, H335 P210, P261, P305 + P351 + P338 concentrated sulfuric acid (H2SO4): H290, H314 P280, P301 + P330 + P331, P303 + P361 + P353, P305 + P351 + P338, P310 malonic acid (CH2(CO2H)2): H302, H318 P273, P305 + P351 + P338 The chemicals cause very severe skin burns and eye damage. Therefore, it is absolutely necessary to wear a lab coat, safety goggles and protective gloves. Because bromine is produced during the preparation, this step should be performed in a fume hood. Procedure: Preparation: The following solutions have to be prepared: Solution A: 2 mL of concentrated sulfuric acid are added to 67 mL of deionized water. Subsequently, 5 g of sodium bromate are dissolved in the acidic solution. Solution B: 1 g of malonic acid is dissolved in 10 mL of deionized water. Solution C: 1 g of sodium bromide is dissolved in 10 mL of deionized water. Under a fume hood, a 100 mL beaker is placed on the magnetic stirrer. 12 mL of solution A are poured into the beaker. Subsequently, 2 mL of solution B and 1 mL of solution C are www.job-foundation.org added while stirring. After the addition of the last solution, one can observe a yellow brown color caused by the production of bromine.
  • Calcium Bromide Liquid: Safety and Handling Guide Geobrom® HG520

    Calcium Bromide Liquid: Safety and Handling Guide Geobrom® HG520

    Calcium Bromide Liquid Safety and Handling Guide GeoBrom® HG520 Great Lakes Solutions: brominated derivative products for mercury control Contents Emergency Response Telephone Numbers 1 Responsible Care®– Doing the Right Thing 2 Introduction 3 GeoBrom® HG520 Product Description 5 Product Description Typical Product Quality Physical and Chemical Properties Environmental, Health, Safety and Regulatory Summary Regulatory Information and Training 9 Procedures for the Safe Handling of Calcium Bromide Liquid 11 Product Data Sheet Personal Protective Equipment (PPE) Safety and Handling Safety Considerations Environmental Considerations Spills Recommended Storage and Security Emergency Procedures 13 Emergency Equipment and Supplies Transportation Emergencies Fire First Aid 14 Equipment and Materials of Construction 16 Corrosion Studies Summary Shipping Containers and Transportation 17 Contact Information 19 Emergency Response Telephone Numbers for Bromine Country/ Emergency Response Provider and Region Emergency Number* CHEMTREC® United States +1-800-424-9300 or 1-703-527-3887 Carechem 24 Europe +44 (0) 1235 239 670 Carechem 24 India +91 1166 4114 05 National Registration Centre for Chemicals (NRCC) China 0532-8388-9090 *Refer to the Safety Data Sheet (SDS) for additional regional emergency response phone numbers. 1 | GLS GeoBrom® HG520 CaBr2 Liquid Safety and Handling Guide Responsible Care®– Doing the Right Thing Responsible Care® is the chemical Our Responsible Care® Policy industry’s health, safety, security, Chemtura considers ensuring the safety and health of the public, our employees, and environmental performance contractors, and customers and the protection of the environment now and improvement initiative. As an for future generations to be our core values. We are committed to meeting obligation of membership, all applicable laws, regulations, permits, and internal standards throughout Responsible Care® is the ethical the world.
  • Zinc-Calcium Bromide Solution

    Zinc-Calcium Bromide Solution

    TETRA Technologies, Inc. Material Safety Data Sheet Zinc-Calcium Bromide Solution 1. PRODUCT AND COMPANY IDENTIFICATION U.S. Toll Free (800) 424-9300 CHEMTREC (24-Hr Emergency Response): TETRA Technologies, Inc. International +1 703-527-3887 25025 I-45 North Poison Control: (800) 222-1222 The Woodlands, TX 77380 Non-emergency Customer Service: (281) 367-1983 Synonyms: Zinc-Calcium Bromide, Liquid Zinc-Calcium Bromide Chemical Family: Inorganic Salt Solution MSDS Creation Date: 08 Oct 96 MSDS Revision Date: 09 Apr 08 2. HAZARDS IDENTIFICATION NFPA Ratings: (Scale 0-4) Health: 2 Fire: 0 Reactivity: 0 WARNING: Irritant; Marine Pollutant; Explosion potential with mixtures containing potassium or sodium. Odorless, clear, colorless to amber liquid. May cause irritation to skin, eyes and respiratory system. Avoid breathing mists, EMERGENCY OVERVIEW: contact with eyes, skin and clothing. Harmful if swallowed. Do not ingest. Keep container tightly closed. Wash thoroughly after handling. Keep container tightly closed. Wash thoroughly after handling. Use only with adequate ventilation. Potential Health Effects Dermal sensitizer. Single, short exposure not likely to cause significant skin irritation. However, direct contact with solution may cause irritation, redness and Skin Contact: pain, possibly severe. Additional effects may include blistering, erythema, exfoliation, ulceration, necrosis, and scarring. May cause irritation of eyes with redness and pain and superficial injury. Additional Eye Contact: effects may include tearing, eye discharge, conjunctivitis, and blurred vision. Inhalation may cause irritation to mucous membranes and respiratory system. Inhalation: Additional effects may include coughing, labored breathing, and shortness of breath. Ingestion may cause burning sensation in mouth and throat, yellowing of the skin and eyes, nausea, vomiting, diarrhea, blood in urine, inability to urinate, low blood Ingestion: pressure, blood disorders, kidney damage, liver damage, convulsions and unconsciousness.